WO2011151618A3 - Compounds for the treatment of clostridium difficile associated disease (cdad) - Google Patents

Compounds for the treatment of clostridium difficile associated disease (cdad) Download PDF

Info

Publication number
WO2011151618A3
WO2011151618A3 PCT/GB2011/000828 GB2011000828W WO2011151618A3 WO 2011151618 A3 WO2011151618 A3 WO 2011151618A3 GB 2011000828 W GB2011000828 W GB 2011000828W WO 2011151618 A3 WO2011151618 A3 WO 2011151618A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
treatment
clostridium difficile
cdad
associated disease
Prior art date
Application number
PCT/GB2011/000828
Other languages
French (fr)
Other versions
WO2011151618A2 (en
Inventor
Peter David Johnson
Richard Vickers
Francis Xavier Wilson
Colin Richard Dorgan
Olivier De Moor
Stephen Paul Wren
Lauren Jayne Sudlow
Renate Van Well
Original Assignee
Summit Corporation Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1009094.2A external-priority patent/GB201009094D0/en
Priority claimed from GBGB1106970.5A external-priority patent/GB201106970D0/en
Application filed by Summit Corporation Plc filed Critical Summit Corporation Plc
Publication of WO2011151618A2 publication Critical patent/WO2011151618A2/en
Publication of WO2011151618A3 publication Critical patent/WO2011151618A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Disclosed are compounds of formula (I): or a pharmaceutically acceptable N-oxide, salt, hydrate, solvate, complex, bioisostere, metabolite or prodrug thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.
PCT/GB2011/000828 2010-06-01 2011-06-01 Compounds for the treatment of clostridium difficile-associated disease WO2011151618A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1009094.2A GB201009094D0 (en) 2010-06-01 2010-06-01 Compounds for the treatment of closridium difficile-associated disease
GB1009094.2 2010-06-01
GBGB1106970.5A GB201106970D0 (en) 2011-04-27 2011-04-27 Compounds for the treatment of clostridium difficile-associated disease
GB1106970.5 2011-04-27

Publications (2)

Publication Number Publication Date
WO2011151618A2 WO2011151618A2 (en) 2011-12-08
WO2011151618A3 true WO2011151618A3 (en) 2012-03-08

Family

ID=44947122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/000828 WO2011151618A2 (en) 2010-06-01 2011-06-01 Compounds for the treatment of clostridium difficile-associated disease

Country Status (1)

Country Link
WO (1) WO2011151618A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103282034A (en) * 2010-11-18 2013-09-04 利亘制药公司 Use of hematopoietic growth factor mimetics
KR101585288B1 (en) 2012-05-31 2016-01-14 주식회사 엘지화학 Aromatic compound and organic solar cell comprising the same
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
US11168062B2 (en) 2016-09-12 2021-11-09 University Of Notre Dame Du Lac Compounds for the treatment of Clostridium difficile infection
BR112022000484A2 (en) * 2019-07-17 2022-03-08 Summit Oxford Ltd Ridinylazole preparation process and crystalline forms thereof
KR102296290B1 (en) * 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 Bifidobacterium adolescentis strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076009A2 (en) * 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
WO2011046954A1 (en) * 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3696495A (en) 1994-11-17 1996-06-17 F. Hoffmann-La Roche Ag Antibacterial dibenzimidazole derivatives
AP2003002824A0 (en) 2000-12-15 2003-09-30 Vertex Pharma Gyrase inhibitors and uses thereof
KR101052433B1 (en) 2002-06-13 2011-07-29 버텍스 파마슈티칼스 인코포레이티드 2-ureido-6-heteroaryl-3H-benzoimidazole-4-carboxylic acid derivatives as gyrase and / or topoisomerase IV inhibitors and pharmaceutical compositions for treating bacterial infections comprising the same
WO2004041209A2 (en) 2002-11-01 2004-05-21 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
AU2006345003A1 (en) 2005-08-12 2008-04-10 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
CA2626685A1 (en) 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076009A2 (en) * 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
WO2011046954A1 (en) * 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKASHI, HIROYOSHI: "Reactions and applications of itaconic acid. XV. Synthesis of heat resistant polymers from the reaction products between itaconic acid and two aromatic diamines", MEMOIRS OF THE FACULTY OF ENGINEERING, KOBE UNIVERSITY , NO. 16, 162-74 CODEN: MFEKAF; ISSN: 0368-9638, 1970 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1970, AKASHI, HIROYOSHI: "Reactions and applications of itaconic acid. XV. Synthesis of heat resistant polymers from the reaction products between itaconic acid and two aromatic diamines", XP002666796, retrieved from STN Database accession no. 1970:415332 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1972, YOKOTA, RIKIO ET AL: "Evaluation of the thermal stability of high polymers by thermogravimetry. Poly(benzimidazole) and its model compounds", XP002666795, retrieved from STN Database accession no. 1972:540641 *
YOKOTA, RIKIO ET AL: "Evaluation of the thermal stability of high polymers by thermogravimetry. Poly(benzimidazole) and its model compounds", KOBUNSHI KAGAKU , 29(6), 428-31 CODEN: KOKAAM; ISSN: 0023-2556, 1972 *

Also Published As

Publication number Publication date
WO2011151618A2 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
CA2801274C (en) Compounds for the treatment of clostridium difficile-associated disease
WO2011151618A3 (en) Compounds for the treatment of clostridium difficile associated disease (cdad)
WO2013012915A8 (en) Heterocyclic compounds and uses thereof
PL3683209T3 (en) Process for preparing [(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)-amino]acetic acid from 5-((3-chlorophenyl)-3-chloro-pyridin-2-yl)-nitrile, and process for preparing 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives
WO2014036219A3 (en) Methods and compositions for treatment of a genetic condition
MX2013011591A (en) Methods and compositions for treating neurodegenerative diseases.
WO2012064973A3 (en) Heterocyclic compounds and uses thereof
MX2013011589A (en) Methods and compositions for treating parkinson's disease.
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
MX2014002552A (en) Pyrazole compound and use thereof for medical purposes.
HK1200367A1 (en) 4-pregenen-11ss-17-21-triol-3, 20-dione derivatives for the treatment of ocular conditions 4--11ss-17-21--320-
MX2016009794A (en) Heterocyclic sulfonamide derivative and medicine comprising same.
WO2013173759A3 (en) Macrocyclic nucleoside phosphoramidate derivatives
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX2012002528A (en) Therapeutic agent for mood disorders.
GB201101517D0 (en) Receptor antagonists
ZA201401710B (en) "new administration regime for n-hydroxy-4-{-3-(n,n-dimethylamethyl)benzofurun-2 ylcarbonylamino]ethoxy}benzaminde"
WO2013152065A3 (en) 1,8-naphthyridin-2(1h)-one derivatives as cytomegalovirus inhibitors
WO2014068587A3 (en) An improved process for the synthesis of dabigatran and its intermediates
WO2012030170A3 (en) Novel compound acting as a cannabinoid receptor-1 inhibitor
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
TN2012000093A1 (en) Therapeutic agent for anxiety disorders

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11782180

Country of ref document: EP

Kind code of ref document: A2